410 related articles for article (PubMed ID: 30575489)
1. Fracture Prevention with Zoledronate in Older Women with Osteopenia.
Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Wong S; Wiessing KR; Bolland MJ; Bastin S; Gamble GD
N Engl J Med; 2018 Dec; 379(25):2407-2416. PubMed ID: 30575489
[TBL] [Abstract][Full Text] [Related]
2. Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.
Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Wiessing KR; Bolland MJ; Bastin S; Gamble GD
J Intern Med; 2019 Aug; 286(2):221-229. PubMed ID: 30887607
[TBL] [Abstract][Full Text] [Related]
3. Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years.
Reid IR; Horne AM; Mihov B; Bava U; Stewart A; Gamble GD
Lancet Diabetes Endocrinol; 2024 Apr; 12(4):247-256. PubMed ID: 38452783
[TBL] [Abstract][Full Text] [Related]
4. Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
Siris ES; Simon JA; Barton IP; McClung MR; Grauer A
Osteoporos Int; 2008 May; 19(5):681-6. PubMed ID: 17968610
[TBL] [Abstract][Full Text] [Related]
5. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
Huang J; Meixner L; Fernandez S; McCutchan JA
AIDS; 2009 Jan; 23(1):51-7. PubMed ID: 19050386
[TBL] [Abstract][Full Text] [Related]
6. Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women.
Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Bastin S; Gamble GD
J Bone Miner Res; 2020 Jan; 35(1):20-27. PubMed ID: 31603996
[TBL] [Abstract][Full Text] [Related]
7. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
8. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
[TBL] [Abstract][Full Text] [Related]
10. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
11. Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial.
Grey A; Horne A; Gamble G; Mihov B; Reid IR; Bolland M
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 32016386
[TBL] [Abstract][Full Text] [Related]
12. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate.
Bourke S; Bolland MJ; Grey A; Horne AM; Wattie DJ; Wong S; Gamble GD; Reid IR
Osteoporos Int; 2013 Jan; 24(1):349-54. PubMed ID: 22893357
[TBL] [Abstract][Full Text] [Related]
13. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
[TBL] [Abstract][Full Text] [Related]
14. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
[TBL] [Abstract][Full Text] [Related]
15. Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis.
Gazoni FM; Civile VT; Atallah ÁN; Santos FC; Trevisani VFM
Sao Paulo Med J; 2023; 141(6):e2022480. PubMed ID: 37255065
[TBL] [Abstract][Full Text] [Related]
16. Efficiency of Zoledronic Acid in Inhibiting Accelerated Periprosthetic Bone Loss After Cementless Total Hip Arthroplasty in Osteoporotic Patients: A Prospective, Cohort Study.
Fu GT; Lin LJ; Sheng PY; Li CC; Zhang JX; Shen J; Liu S; Xue YL; Lin SP; Wang K; Zheng QJ; Ding Y
Orthop Surg; 2019 Aug; 11(4):653-663. PubMed ID: 31456320
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid and clinical fractures and mortality after hip fracture.
Lyles KW; Colón-Emeric CS; Magaziner JS; Adachi JD; Pieper CF; Mautalen C; Hyldstrup L; Recknor C; Nordsletten L; Moore KA; Lavecchia C; Zhang J; Mesenbrink P; Hodgson PK; Abrams K; Orloff JJ; Horowitz Z; Eriksen EF; Boonen S;
N Engl J Med; 2007 Nov; 357(18):1799-809. PubMed ID: 17878149
[TBL] [Abstract][Full Text] [Related]
19. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Saag KG; Petersen J; Brandi ML; Karaplis AC; Lorentzon M; Thomas T; Maddox J; Fan M; Meisner PD; Grauer A
N Engl J Med; 2017 Oct; 377(15):1417-1427. PubMed ID: 28892457
[TBL] [Abstract][Full Text] [Related]
20. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
